The U.S. Food and Drug Administration handed approval to Pennsylvania-based pharmaceutical developer Mylan on June 4 for its biosimilar of Amgen’s Neulasta. Neulasta sales slipped 2 percent in 2017, but still brought the regional biotech giant more than $4.5 billion, or around a fifth of its revenue and second only to blockbuster rheumatoid arthritis drug…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
